X-82 to Treat Age-related Macular Degeneration

NCT02348359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

157

Enrollment

INDUSTRY

Sponsor class

Stopped Interim analysis found study had achieved primary objective

Conditions

Age-Related Macular Degeneration (AMD)
Macular Degeneration
Exudative Age-related Macular Degeneration
AMD
Macular Degeneration, Age-related, 10
Eye Diseases
Retinal Degeneration
Retinal Diseases

Interventions

DRUG: X-82
DRUG: Anti-VEGF
DRUG: Placebo

Sponsor

Tyrogenex

Collaborators

[object Object]
[object Object]